• Assay Search

Celerion

committed to service excellence

Primary Navigation for Celerion

  • Home
  • About Celerion
    • Why Celerion?
    • Mission, Vision and Credo
    • Management Team
    • Who We Work With
      • New Drug Candidates
      • NDA/MAA-enabling Studies
      • Generic Drugs/Biosimilars
    • Locations
    • Environmental Sustainability
  • Applied Translational Medicine
    • Key Elements of Success
  • Services
    • Global Clinical Research
      • Phase I and ll Studies
      • Study Experience
      • In-hospital Beds
      • Cardiovascular Safety Services
      • Highly Automated ECG Core Lab
      • Metabolic Diseases
      • NAFLD/NASH
      • Belfast – Center of Excellence for Respiratory
      • ADME/Mass Balance
      • Microtracer Studies
      • USP <797> Clean Room
      • ClinQuick® Electronic Data Acquisition
      • AAHRPP Accreditation
      • Recruitment
    • Global Clinical Development
      • Vaccines
    • Data Management and Biometrics
      • Modeling and Simulation
      • Study Design and Protocol Development
      • Clinical Data Sciences
      • Biostatistics
      • Pharmacokinetics/Pharmacodynamics (PK/PD)
      • Medical Writing and Reporting
      • Streamlined Data Flow Process – Internal Studies
      • Streamlined Data Flow Process – Multi-Site Studies
    • Global Bioanalytical Services
      • Assay Search
      • Small Molecule
      • Large Molecule
      • Biosimilars
      • Electronic Laboratory Notebook System
      • ADME/Mass Balance
    • Drug Development Services
      • Biopharmaceutical Development
      • Program Management
      • Regulatory Affairs
  • Celerion Europe
    • Global Clinical Research
    • Global Clinical Development
      • Vaccines
    • Data Management and Biometrics
    • Global Bioanalytical Services
  • Celerion Asia
  • Tobacco Risk Evaluation
    • Protocol Development and Data Interpretation
    • Global Clinical Research
    • Global Bioanalytical Services
    • Global Regulatory Services
  • Case Studies
    • Global Clinical Research
      • Responding to an Unexpectedly High Drop Rate
      • Mass Balance Study
      • Semen Clinical Studies
    • Data Management and Biometrics
      • Partnering with Biotechnology Companies
      • Partnering with Large Pharmaceutical Companies
      • Protocol Study Design and Development for Generic Studies
      • Difficult to Recruit Population
      • Consistent Database Structure for Programs of Studies
    • Global Bioanalytical Services
      • Improved Desmopressin Analysis of Clinical Samples
      • Optimized LC-MS/MS Method for New Observed Metabolite
      • Bioanalytical Support of Oncology Studies
      • High Throughput Bioanalytical Analysis
      • Partnering with Biotechnology Companies
      • Partnering with Pharmaceutical Companies
      • Development of an LC-MS/MS Peptide Method
    • Drug Development Services
      • Customized Program Planning for Opening IND Study
      • Support of CMC to IND for Novel First-in-Class Small Molecule Drugs
      • Rapid Proof-of-Concept for Novel Drug Treatment for Rare Metabolic Disease
      • Proof-of-Concept Efficacy Clinical Study
      • European Biotechnology Company Seeking First-in-Human U.S. Clinical Study
      • Asian Biotechnology Company with CNS Compound
  • White Papers
  • Other Resources
  • Celerion Video Library
  • News & Events
    • Blog
    • Press Room
    • Conferences/Events
    • Clinical Discussion Forums
      • Past Clinical Discussion Forums
  • Participate in a Study
  • Careers
  • Celerion Science Newsletter 2018 Q2
  • Celerion Science Newsletter 2018 Q1
  • Celerion Science Newsletter 2017 Q4
  • Celerion Science Newsletter 2017 Q3
  • Celerion Science Newsletter 2017 Q2
  • Celerion Science Newsletter 2017 Q1
  • Celerion Science Newsletter 2016 Q3

Services > Global Clinical Research

NAFLD/NASH

Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH)

Unparalleled Expertise

Celerion has vast experience with NAFLD/NASH investigation products, and understands the importance of detecting early signals of efficacy. With more than 10 years of metabolic research experience, our knowledgeable team of subject matter experts offers scientific and operational oversight across all lines of service.

Extensive Experience

As a leader in early clinical research, Celerion assists our clients with their “go/no-go” decisions. A breadth of pharmacodynamic services enables clients to examine the effect of NAFLD/NASH investigational products on hepatic lipid metabolism and fibrosis development. Celerion’s range of services includes:

  • Fasting and postprandial lipid measurements
  • Hepatic de novo lipogenesis by stable-label isotope tracer
  • Lipid clearance assessments
  • Indirect calorimetry
  • Fingerstick ketones
  • Ultrasound and MRI imaging

Celerion also has access to a number of soluble biomarkers of fibrosis and inflammation as well as lipidomic and metabolomic analyses.

Special Populations

With locations in the heart of culturally diverse cities, Celerion’s multi-centered sites offer effective recruiting strategies for healthy subjects and patients from disparate populations with a high prevalence of fatty liver disease. Moreover, we have established partnerships with a number of national health and community-based organizations to support our recruitment efforts.

Learn more about our Metabolic Disease services

See also…

Global Bioanalytical Services

Article: A Fatty World: Exploring Racial Disparity in NAFLD/NASH

White Paper: Challenges and Solutions with Bioanalysis of Soluble Biomarkers: A Case Study for Non-Invasive NASH Biomarkers

White Paper: NAFLD/NASH and Non-Invasive Biomarkers Predicting Fibrosis

Published Article: Clinical Assessment of Hepatic De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease

Video: Metabolic Disease

For more information contact us

  • LinkedIn
  • YouTube
  • Twitter

Footer Naviation

  • About
  • Locations
  • Careers
  • Request a Proposal
  • Contact
  • Privacy Policy
© 2019 Celerion | Web Design by Aradius Group